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Abstract
Partial cleavage of p120 RasGAP by caspase-3 in stressed cells generates an N-terminal fragment, called fragment N, which
activates an anti-apoptotic Akt-dependent survival response. Akt regulates several effectors but which of these mediate
fragment N-dependent cell protection has not been defined yet. Here we have investigated the role of mTORC1, Bad, and
survivin in the capacity of fragment N to protect cells from apoptosis. Neither rapamycin, an inhibitor of mTORC1, nor
silencing of raptor, a subunit of the mTORC1 complex, altered the ability of fragment N from inhibiting cisplatin- and Fas
ligand-induced death. Cells lacking Bad, despite displaying a stronger resistance to apoptosis, were still protected by
fragment N against cisplatin-induced death. Fragment N was also able to protect cells from Fas ligand-induced death in
conditions where Bad plays no role in apoptosis regulation. Fragment N expression in cells did neither modulate survivin
mRNA nor its protein expression. Moreover, the expression of cytoplasmic survivin, known to exert anti-apoptotic actions in
cells, still occurred in UV-B-irradiated epidermis of mouse expressing a caspase-3-resistant RasGAP mutant that cannot
produce fragment N. Additionally, survivin function in cell cycle progression was not affected by fragment N. These results
indicate that, taken individually, mTOR, Bad, or Survivin are not required for fragment N to protect cells from cell death. We
conclude that downstream targets of Akt other than mTORC1, Bad, or survivin mediate fragment N-induced protection or
that several Akt effectors can compensate for each other to induce the pro-survival fragment N-dependent response.
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Introduction
Activation of executioner caspases was once believed to
represent a point of no return in the path to death. However it
is now well established that while executioner caspases are
indispensable for apoptosis, there are situations when their
activation does not lead to death. For example, healthy dividing
cells can weakly activate caspase-3 in response to mild stresses [1].
Caspase-3 also participates, in an apoptosis-independent manner,
in T and B cell homeostasis [2,3], in microglia activation [4], and
in muscle [5], monocyte [6], bone marrow stromal stem cell [7],
and erythroid cell differentiation [8].
Low caspase-3 activation in stressed cells induces the partial
cleavage of RasGAP into an amino-terminal fragment, called
fragment N, that prevents amplification of caspase-3 activation
and death in an Akt-dependent manner [9]. Knock-in mice that
only express a caspase-3-resistant RasGAP mutant, and hence that
cannot generate fragment N in response to stress, are unable to
stimulate Akt efficiently and are more sensitive to damage induced
by various pathophysiological insults [10]. Fragment N generation
can therefore explain why cells having mildly activated caspase-3
do not necessarily die. On the other hand, when caspase-3 activity
is strongly stimulated in cells, fragment N is further processed into
smaller fragments, called N1 and N2, that no longer have the
capacity to activate Akt [11]. The extent of caspase-3 activity in a
cell can therefore be sensed by RasGAP to either mount an
efficient Akt-dependent protection when the stress is not too strong
[1,12] or to abrogate this protective signal in cells faced with
strong insults or apoptotic stimuli [11].
Phosphorylation of downstream effectors by Akt leads to diverse
cellular responses affecting metabolism, protein synthesis, prolif-
eration, angiogenesis and inhibition of apoptosis [13]. A series of
Akt effectors have been shown to favor survival once phosphor-
ylated by Akt [13,14]. These can be either pro-apoptotic proteins
that become inactivated once phosphorylated by Akt or anti-
apoptotic proteins the expression of which is induced by Akt. In
the first group lie Bad, Bax, Ask1, and pro-apoptotic transcription
factors such as YAP and some Forkhead family members. Mdm2,
a p53 inhibitor, members of the inhibitor of apoptosis family (c-
IAP1/2, survivin), members of the anti-apoptotic Bcl-2 subfamily
(A1, Bcl-XL) and the NF-kB transcription factor, which is generally
inducing survival responses, are found in the second group [15–
18].
Although Akt can lead to activation of the NF-kB transcription
factor, fragment N-mediated Akt activation does not result in NF-
kB stimulation [19]. In fact, fragment N is able to block NF-kB
activation in response to various stimuli including exposure to
inflammatory cytokines [20,21]. Hence fragment N does not rely
on NF-kB activation to protect cells. Actually, a sustained NF-kB
activation could be detrimental at least in certain cell types, such as
pancreatic beta cells [22]. In this context, the capacity of fragment
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N to block NF-kB activation would be beneficial and it has indeed
been shown that NF-kB inhibition by fragment N contributes to its
anti-apoptotic activity in beta cells [21,23]. These observations
rule out activation of NF-kB as an Akt-dependent mechanism used
by fragment N to protect cells. Which of the other Akt effectors are
required for fragment N to protect cells is not known.
In the present work we investigated whether mTORC1, Bad
and survivin play a role in fragment N-mediated apoptosis
inhibition. Mammalian TOR (mTOR) is a protein kinase that
exists in two different complexes. The mTORC1 complex
contains mTOR and Raptor and is inhibited by rapamycin. Akt
indirectly activates mTORC1 by preventing the TSC1/TSC2
GTPase-activating proteins from inhibiting Rheb, the small GTP-
binding protein that stimulates mTORC1. The mTORC2
complex, which contains mTOR and Rictor, is not sensitive to
rapamycin, at least in short-term experiments [24], and positively
regulates the activation of Akt by phosphorylating it rather than
being an Akt effector itself [25,26]. The involvement of mTORC1
in the control of cell survival responses [27,28] makes it a possible
fragment N effector candidate.
Another putative player in fragment N-induced protective
pathway is Bad, a pro-apoptotic member of the Bcl-2 family
[29,30]. When phosphorylated by Akt, Bad binds to 14-3-3
proteins and this prevents its capacity to interact with anti-
apoptotic Bcl-2 family members. Consequently, phosphorylated
Bad loses its pro-apoptotic activity [31].
Survivin (also called BIRC5), an atypical member of the
inhibitor of apoptosis (IAP) family of proteins, is also a component
of the chromosomal passenger protein complex that ensures
proper segregation of sister chromatids and cytokinesis [32,33],
and that mediates many other functions during mitosis [34]. The
absence of survivin profoundly alters mitosis and cytokinesis and
this eventually leads to cell death [32,35]. The exact contribution
of survivin in anti-apoptotic responses is controversial and still not
well defined. Survivin may indirectly affects caspases either by
binding and stabilizing XIAP [36], blocking Smac-dependent
XIAP inhibition [19,24,30,33] or inhibiting caspase-9 by cooper-
ating with HBXIP [23]. Depending on the cell types and the
experimental conditions, activation of Akt can lead to increased
survivin expression [37,38].
Materials and Methods
Plasmids
pEGFP-C1 (#6) encodes the green fluorescent protein and is
from Clontech. The.dn3,.lti,.gl3, and.ebg extensions indicate that
the backbone plasmid is pcDNA3 (Invitrogen), a lentiviral vector,
pGL3 basic (Promega) and pEBG (Addgene), respectively. HA-
hRasGAP[1-455](D157A).dn3 (#352) encodes a tagged and
caspase-3-resistant version of the 1–455 amino acid fragment of
human RasGAP (fragment N); previously called N-D157A.dn3 in
[12]. HA-hRasGAP[1–455](D157A).lti (#353) is the plasmid
used for the production of the lentivirus encoding the caspase-
resistant form of fragment N; previously called N-D157A.lti in [1].
GFP-HA-hRasGAP[1–157] (#231) encodes a fusion protein
between GFP and fragment N1 (amino acid 1–157 of human
RasGAP). It was generated by subcloning the ApaI/HindIII
fragment of plasmid HA-hRasGAP[1–158].dn3 (#147; previously
called HA-N1.dn3 in [12]) into pEGFP-C3 (#98; Clontech)
opened with the same enzymes. GFP-HA-hRasGAP[157–455]
(#213), previously described as GFP-HA-N2 in [39], encodes a
fusion protein between GFP and fragment N2 (amino acid 158–
455 of human RasGAP). GST-mBad.ebg (#271) is a mamma-
lian expression vector encoding a fusion protein between
glutathione S-transferase (GST) and full-length murine Bad. It
was purchased from Cell Signaling under the name pEBG-MBad.
SIN-PGK-hBcl2-WHV (#359) was used for the production of
Bcl2-encoding lentiviruses [23]. mE2F1.sport6 (#675) encodes
the mouse E2F1 transcription factor. It was purchased from
Imagenes. Mouse survivin promoter plasmids were obtained by
cloning the sequences corresponding to the entire survivin
promoter (21297 to +13) or a shorter sequence containing the
minimal sequences required for its activation (2209 to +13)
[40,41] into the pGL3 basic promoterless luciferase gene-bearing
plasmid (#95). The resulting plasmids were called mSurvivin
promoter [21297 to +13].gl3 (#634) and mSurvivin
promoter [2209 to +13].gl3 (#633), respectively. mSurvivin
promoter [21297 to +13].gl3 was generated as follows. The
genomic DNA of the FVB/N-tg(RIP::N)1Wid mouse [20]
(European Mouse Mutant Archive accession nuEM:05139) was
PCR-amplified using the sense primer #655: AAAAAA (feeder)
CTCGAG (XhoI) CACCTCTTACTCCACACC TG (nucleo-
tides 49001–49020 of the mouse chromosome 11 genomic contig
NT_165773) and the anti-sense primer #656: AAAAAA (feeder)
AAGCTT (HindIII) CCG GAG CTC CCA TGA TGG CG
(nucleotides 50310-50291 of the mouse chromosome 11 genomic
contig NT_165773). The resulting 1134 base pair fragment was
cut with XhoI and HindIII and sub-cloned in pGL3-basic (#95)
opened with the same enzymes. mSurvivin promoter [2209 to
+13].gl3 was generated as follows. Plasmid mSurvivin promoter
[21297 to +13].gl3 (#634) was PCR-amplified using the sense
primer #657: AAAAAA (feeder) CTCGAG (XhoI)
ATGCCCTGCGCCCGCCACGC (nucleotides 50089–50108 of
the mouse chromosome 11 genomic contig NT_165773) and the
anti-sense primer #656 (see above). The resulting PCR fragment
was cut with XhoI and HindIII and subcloned in pGL3-basic
opened with the same enzyme. pRL-TK (#402) encodes the
Renilla luciferase.
Cell Culture and Chemicals
The RasGAP+/+ mouse embryonic fibroblasts (MEFs; clone
12.78), the RasGAP2/2 MEFs (clone 12.64), and their derivatives
stably expressing wild-type RasGAP or the caspase-resistant
D455A mutant [11,42] were maintained in DMEM (Invitrogen,
catalogue nu61965) containing 10% newborn calf serum (Invitro-
gen, catalogue nu 26010-074) at 37uC and 5% CO2. BAD knock-
out MEFs were cultured similarly. Mouse beta cells (MIN6) cells
were maintained in modified DMEM complemented with
0.1 mM b-mercaptoethanol and 1 mM sodium pyruvate. HeLa
cells were maintained in RPMI 1640 (Invitrogen catalogue
nu61870) containing 10% newborn calf serum at 37uC and 5%
CO2. Cisplatin (catalogue nuP4394) and rapamycin (catalogue
nuR0395) were purchased from Sigma. Hexameric Fas ligand,
resulting from the aggregation of 6 fusion proteins between Fas
ligand and the Fc portion of IgG1 [43], was provided by Pascal
Schneider (University of Lausanne). Staurosporine was purchased
from Roche Diagnostics (Basel, Switzerland) (catalogue
nu1055682).
Antibodies
The anti-p70 S6 kinase antibody, the anti-raptor antibody, the
anti-phospho Bad antibody sampler kit and the rabbit anti-
survivin 71G4 monoclonal antibody were purchased from Cell
Signaling Technology (catalogue nu9205, 2280, 9105 and 2808
respectively). The monoclonal anti-a tubulin antibody was
purchased from Serotec, Oxford, UK (catalogue nuMCA77G).
Secondary antibodies used for Western blotting were Alexa Fluor
680–conjugated anti-rabbit antibody (Molecular Probes, Eugene,
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Figure 1. mTORC1 is not involved in fragment N-induced cell survival. HeLa cells were transfected with a GFP-expressing plasmid together
with empty pcDNA3 or with pcDNA3 encoding the D157A caspase-resistant form of fragment N. Twenty-four hours later, the cells were incubated 90
minutes with 20 ng/ml rapamycin or with vehicle alone (DMSO). A. The cells were lysed after an additional 24-hour period and the extent of S6K
phosphorylation was assessed by Western blot. B-C. Following the rapamycin pre-incubation period, the cells were treated or not with 10 mM
cisplatin (panel B) or with 5 ng/ml Fas ligand (panel C) for 24 hours and apoptosis was scored (mean 695% CI of 5 and 3 independent experiments,
respectively, performed in monoplicate). D. HeLa cells were transfected or not with siRNAs directed at Raptor and one day later transfected with
empty pcDNA3 or with pcDNA3 encoding fragment N. After an additional 24-, 48-, or 72-hour period, the cells were lysed to assess the levels of
Raptor expression. E. Alternatively, one day following the pcDNA3 plasmid transfection, the cells were treated with cisplatin (30 mM) for 24 more
hours and apoptosis was then scored (mean 695% CI of 3 independent experiments performed in monoplicate). Asterisks denote statistically
significant differences [one-way ANOVAs followed by pair-wise Dunn (Bonferroni) post hoc t tests].
doi:10.1371/journal.pone.0068123.g001
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OR; catalogue nuA21109) or IRDye 800–conjugated anti-mouse
antibody (Rockland, Gilbertsville, PA; catalogue nu610-132-121).
For immunohistochemistry the secondary antibody was Cy3-
conjugated AffiniPure Fab fragment goat anti-rabbit IgG (cata-
logue nu711-165-152) and was purchased from Jackson Immu-
noResearch Laboratories.
Lentivirus
Recombinant lentiviruses were produced as described [44]. The
minimal amounts of viruses inducing expression of the protein of
interest in more than 95% of the cells (as assessed by
immunofluorescence) were used.
Transfection and Luciferase Assay
HeLa cells were transfected with Lipofectamine 2000 (Invitro-
gen) as described earlier [12]. MIN6 cells (3?105) were co-
transfected using Lipofectamine with 0.5 mg of mSurvivin
promoter [21297 to +13].gl3 or mSurvivin promoter [2209 to
+13].gl3, 0.5 mg of a Renilla-encoding plasmid and 1 mg of either
HA-hRasGAP[1–455](D157A).dn3 or mE2F1.sport6. The empty
pcDNA3 or SPORT6.1 vectors were used as negative controls.
Cells were harvested 36 hours after transfection and luciferase
activity was measured using Dual-LuciferaseH Reporter Assay
(Promega). Signals were detected with GLOMAXTM 96 Micro-
plate Luminoteter (Promega) and analyzed with Glomax version
1.7.0 program. Results were normalized with Renilla luciferase
activity.
RNAi
HeLa cells were plated in 6-well plates, with a starting density of
2?105 cells per well. After an overnight incubation, the cells were
transfected with 200 pmoles of siRNA for 7 hours using the
calcium phosphate co-precipitation method [45]. siRNAs were
synthesized by Microsynth (Balgach, Switzerland). The Raptor-
directed siRNA sequence was 59-GGACAACGGCCACAAGUA-
39 (nucleotides 2338–2355 found in the coding sequence of human
Raptor transcript 1 mRNA; NCBI reference sequence:
NM_020761.2). Cells were lysed 24, 48, and 72 hours after
transfection for Western blotting analysis.
RNA Extraction and Reverse Transcription
RNA was extracted by lysing cells with 500 ml TRI buffer (1.7
M guanidium thiocyanate, 0.1 M sodium citrate, 0.25% N-lauryl-
sarcosyl sodium, 0.05 M b-mercaptoethanol, 0.1 M sodium
acetate), followed by the addition of 200 ml of chloroform. The
tubes were then vortexed, kept at room temperature for 5 minutes,
and spun at maximal speed in an Eppendorf centrifuge for 15
minutes. After the transfer of the aqueous phase in a new tube,
500 ml of isopropanol was added and the solution was mixed by
inversion approximately five times. The samples were then
incubated o/n at 220uC. After spinning 20 minutes at maximum
speed in an Eppendorf centrifuge, the upper phase (isopropanol)
was aspirated; the pellet was washed twice with 800 ml 70%
ethanol and dried 5–10 minutes at 50uC. The pellet was finally
resuspended in 50 ml of water and RNA was quantitated at
260 nm. Half a microgram of RNA was mixed with 500 ng of
random hexamers (Microsynth, Balgach, Switzerland), and water
was added to reach a final volume of 11 ml. The samples were
incubated 3 minutes at 70uC and then kept on ice. A mix (14 ml)
containing 5 ml of 10 nM dinucleotide triphosphates (Promega
catalogue nuU120D-123D), 0.5 ml of RNasin (Promega catalogue
nuN211A), 5 ml of buffer 56, 2 ml dithiothreitol, 0.5 ml Superscript
reverse transcriptase, and 1 ml water (the 56 buffer, the
dithiothreitol and the transcriptase are coming from the Super-
script II reverse Transcriptase Kit; Invitrogen catalog nu18064-
014) was added to the RNA-hexamer mix. After incubation at
39uC for 1 hour followed by 15 minutes at 70uC, the cDNA was
diluted 1:3 in water.
Real Time PCR
Quantitative PCR assays were carried out on a real-time PCR
detection system (iQ5; Bio-Rad) using iQ SYBR Green Supermix
(Bio-Rad catalog nu170–8862) in which 500 nM primers and 1 ml
of the cDNA template produced as described above were added
(final volume of the reaction: 20 ml). The annealing temperature
was 59uC. Melting curve analyses were performed on all PCR to
rule out nonspecific amplification. Reactions were carried out in
triplicate. The primers used were 59-GCG GAG GCT GGC TTC
A-39 (forward primer) and 59-AGA AAA AAC ACT GGG CCA
AAT C-39 (reverse primer).
Propidium Iodide (PI) Staining and Flow Cytometer
Analysis
HeLa (3?105) cells were seeded in 3.5 cm dishes and infected
with either an empty virus or a virus encoding an HA-tagged form
of fragment N. Seventy-two hours after infection, cells were
synchronized in G1-S phase with 400 mM of mimosine for 18
hours. Cells were released from mimosine blockage by changing
the medium, and harvested at different time points. Cells were
washed twice with 16 PBS and fixed with ethanol 100% for 15
minutes at 220uC. After fixation, cells were spun down at
2000 rpm at 4uC and washed once with 16 PBS. Cells were
resuspended in 1 ml of PI staining buffer (100 mM Tris pH 7,
150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% NP-40,
20 mg/ml RNAse A, 1 mg/ml propidium iodide diluted 1:500)
and put into sorter tubes. After 15 minutes incubation at room
temperature in the dark, the cells were scanned using a Beckman
Coulter FC500 flow cytometer with the following parameters: FSC
95 Volts-1 Gain, SSC 519 Volts-1 Gain, FL3 lin 313 Volts-1 Gain.
Figure 2. Bad modulation plays little role in fragment N-induced cell survival. A. MEFs were infected with an empty lentivirus or with
lentiviruses encoding fragments N, N1, and N2, as indicated. Alternatively, HeLa cells were transfected with a plasmid encoding a GST-Bad fusion
protein with either empty pcDNA3 or with pcDNA3 encoding fragment N. The cells were lysed 24 hours later. The extent of Bad phosphorylation was
assessed by Western blot using antibodies specific for Bad phosphorylated on serine 112 or serine 136. B. Predicted apoptotic response in cells
lacking or not Bad in the presence or in the absence of fragment N. See text for details. C. MEFs expressing or not Bad were infected with an empty
lentivirus or with a fragment N-encoding lentivirus. Forty-eight hours later, the cells were incubated with the indicated concentrations of cisplatin.
Apoptosis was assessed after an additional 24 hour-period. The inset depicts the reduction in the percentage of apoptosis induced by the expression
of fragment N in wild-type or Bad KO cells at the indicated doses (using the values of the main figure). The results correspond to the mean 695% CI
of sextuplets derived from 4 independent experiments. Statistics were done by repeated measures ANOVA tests. D. MEFs were infected with an
empty lentivirus (-), with a Bcl-2 (B)-encoding lentivirus, and with a fragment N (N)-encoding lentivirus, in the indicated combinations. Fourty-eight
hours later, the cells were incubated with 30 ng/ml Fas ligand or 10 nM staurosporine. Apoptosis was assessed after an additional 24 hour-period.
The results correspond to the mean695% CI of 4–8 independent experiments. Asterisks denote statistically significant differences [one-way ANOVAs
followed by pair-wise Dunn (Bonferroni) post hoc t tests]; NS, not significant.
doi:10.1371/journal.pone.0068123.g002
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Figure 3. Fragment N does not regulate survivin expression. A. MIN6 cells were co-transfected with a luciferase expressing vector under the
control of either a minimal promoter sequence allowing the transcription of survivin (left graph) or the entire survivin promoter sequence (right
graph) with increasing amounts of fragment N- (closed circles) or E2F1- (open circles) encoding plasmids. The results correspond to the mean 695%
CI of 6 (left panel) and 3 (right panel) independent experiments performed in triplicate. Repeated measures ANOVA tests were performed to
determine if there was a significant increase in luciferase activity induced by the E2F1- or fragment N-encoding plasmids (normality was verified with
the Shapiro-Wilk test). B–C. MEFs were infected with an empty virus or with a lentivirus encoding the HA-tagged version of the D157A fragment N
mutant. Survivin mRNA levels were analyzed 24 hours later by quantitative RT-PCR (panel B). The location of the 672FW and 672RV primers (red
arrows), used for the amplification of the survivin mRNA, is depicted on top of the graph. Alternatively, cells were lysed and the protein expression of
HA-fragment N and survivin was assessed by Western blotting (panel C). The results correspond to the mean695% CI of 3 independent experiments.
D. Skins of mice were irradiated with low (0.05 J/cm2) and high (0.3 J/cm2) doses of UV-B light. Expression of nuclear and cytoplasmic survivin was
assessed by immunofluorescence in situ (left panel). The quantitation shown on the right-hand side corresponds to percentages of keratinocytes
displaying nuclear or cytoplasmic survivin (mean 695% CI of 6 and 10 mice for the low and high UV-B dose exposure, respectively). No cells were
found to display both cytoplasmic and nuclear survivin expression.
doi:10.1371/journal.pone.0068123.g003
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The population of cells to analyze was gated according to their
size (FSC forward scatter) and granulosity (SCC side scatter) to
exclude dead cells and clumps. Within this cell population cells
were gated according to the peak of intensity versus the integrated
signals to exclude debris and doublets. Ten thousand cells were
analyzed per condition.
Western Blot Analysis
Cells were lysed in monoQ-c buffer [12] and protein
quantification was performed by the Bradford technique. Equal
amounts of protein were migrated in a polyacrylamide gel and
transferred onto a Trans-Blot nitrocellulose membrane (Bio-Rad
catalogue nu10484060). Membranes were blocked with 5% non-
fat milk and incubated over-night at 4uC with specific primary
antibodies. Blots were washed with TBS/0.1% Tween 20,
incubated with specific secondary antibodies and visualized with
the Odyssey infrared imaging system (LICOR Biosciences, Bad
Homburg, Germany). Quantification was performed using the
Odyssey infrared imaging software.
Apoptosis Measurements
Apoptosis in Hela cells was determined by scoring the number
of transfected cells (i.e. cells expressing GFP) displaying pycnotic or
fragmented nucleus [39]. Apoptosis in infected MEFs was similarly
assessed but in all cells.
Immunocytochemistry
HeLa cells were seeded in coverslips. Twenty-four hours later,
coverslips were transferred to a clean dish and the immunocyto-
chemistry was performed. Cells were fixed with 2% paraformal-
dehyde diluted in 16 PBS for 15 minutes at room temperature.
After washing thrice with PBS, cells were permeabilized with 0.2%
Triton X-100 diluted in 16 PBS for 10 minutes at room
temperature. After washing with PBS, unspecific binding sites
were blocked using DMEM culture medium complemented with
10% newborn calf serum. After 20 minutes at room temperature,
the primary anti-HA antibody (1:100 dilution) was added and
incubated for 1 hour at room temperature in a dark and humid
chamber. The secondary antibody was added after three washes in
PBS for 1 hour at room temperature in a dark and humid
chamber. After extensive washes in PBS, nuclei were stained with
10 mMHoechst 33342 (Molecular Probes; catalogue nuH1399) for
Figure 4. Fragment N does not affect cell cycling. HeLa cells, infected with an empty virus or with a lentivirus encoding the HA-tagged version
of the D157A fragment N mutant, were synchronized at G1 by treatment with mimosine for 18 hours. The cells were then washed and cultured in
fresh medium for the indicated periods of time. A. Representative histograms obtained at different time points after release from the mimosine block
(NT, not synchronized cells). B. Immunocytochemistry-based detection (gold staining) of fragment N in the infected cells. The nuclei are colored in
blue (Hoechst staining). C. Percentage of cells in each phase of the cell cycle as determined by PI staining (DNA content). Results represent the mean
695% CI of 4 independent experiments.
doi:10.1371/journal.pone.0068123.g004
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10 minutes before mounting the slides in 0.1 g/ml Mowiol, 0.22%
(v/v) glycerol, Tris 0.1 M pH 8.5, 0.1% diazobicyclo-octane.
Mowiol was from Calbiochem (catalogue nu475904) and diazobi-
cyclo-octane was from Fluka (catalogue nu33480).
Mice and UV-B Irradiation
The RasGAPD455A/D455A knock-in (KI) mice that cannot cleave
RasGAP (C57BL/6N;129/SvEv-Rasa1tm1Wid) have been de-
scribed earlier [10]. UV-B illumination was performed as
described in reference [35].
Immunofluorescence in Skin Sections
Paraffin sections were deparaffinized in two consecutive 5
minute long Xylene 100% baths and rehydrated by successive 2
minute long washes in ethanol 100%, 96%, 75% and 50%.
Immunohistochemistry was performed as described [21]. Nuclei
were stained with 10 mM Hoechst 33342 (Molecular Probes;
catalogue nuH1399) for 10 minutes before mounting the slides in
0.1 g/ml Mowiol, 0.22% (v/v) glycerol, Tris 0.1 M pH 8.5, 0.1%
diazobicyclo-octane. Mowiol was from Calbiochem (catalogue
nu475904) and diazobicyclo-octane was from Fluka (catalogue
nu33480). Quantitation of fluorescent positive cells was performed
as previously described [46].
Data Presentation and Statistics
Results are expressed as the mean 695% confidence intervals
(CI). The statistical tests used were one way ANOVAs unless
otherwise stated. Normality of the data was verified with the
Shapiro-Wilk test.
Results and Discussion
To prevent cleavage of fragment N into the smaller N1 and N2
fragments, which can potentially generate confounding results, the
experiments described below were performed with a form of
fragment N that has its caspase-3 cleavage site destroyed [1,12].
mTORC1 and Fragment N-induced Protection
Rapamycin, a macrolide antibiotic, has been widely used as a
selective inhibitor of the mTORC1 complex and reported as an
inducer of autophagy [47]. Depending on the cellular context and
the concentrations of the drug used, rapamycin can either induce
or inhibit apoptosis [48]. Rapamycin displays cytotoxic effects
when used in micro-molar concentrations [49–51]. These studies
highlight the impact of rapamycin dosage in cell survival outcome.
In our experiments, we used 20 nM of rapamycin that did not
induce, as expected, apoptosis (Figures 1B, 1C) but that was
sufficient to fully block serum-induced phosphorylation of S6
kinase, an mTORC1 substrate (Figure 1A, first two lanes). This
also indicates that mTORC1 is the sole kinase mediating S6K
phosphorylation in serum-cultured HeLa cells. In starved condi-
tions (Figure 1A, third lane), mTORC1 was no longer activated as
indicated by the absence of S6K phosphorylation. As expected
from its ability to stimulate Akt, fragment N activated mTORC1-
dependent S6K phosphorylation (Figure 1A, last two lanes).
However, the ability of fragment N to protect cells from cisplatin-
or Fas ligand-induced apoptosis was unaffected by rapamycin
(Figure 1B), suggesting that mTORC1 activation does not
modulate fragment N-mediated protection. To further substanti-
ate this point, we aimed to disrupt mTORC1 signaling by
silencing Raptor, a protein of the mTORC1 complex [27].
Figure 1D shows that the strongest reduction in Raptor protein
expression levels was achieved 72 hours after the siRNA
transfection. We therefore assessed the ability of fragment N to
protect cells against Fas ligand in which Raptor was silenced for 3
days. Figure 1E shows that Raptor silencing did not influence the
ability of fragment N to inhibit Fas ligand-induced apoptosis. In
conclusion, inhibition of the mTORC1 complex by rapamycin or
via silencing of one of its components (Raptor) did not compromise
the protective capacity of fragment N. Hence, mTORC1 does not
appear to be an essential element targeted by fragment N to
mediate its anti-apoptotic activity in cells.
Phosphorylation of Bad does not Play a Major Role in
Fragment N-mediated Protection
Bad is a pro-apoptotic protein that is blocked from triggering
apoptosis by Akt-mediated phosphorylation on serine 136 [31].
Bad can be phosphorylated by other kinases, such as PKA, on
serine 112 [52]. As expected from its ability to stimulate Akt,
fragment N expressed in HeLa cells led to an increase in Bad
phosphorylation on serine 136 but not on serine 112 (Figure 2A).
Fragments N1 and N2, the fragment N cleavage products
generated by high caspase-3 activity that are unable to stimulate
Akt [11], did not induce Bad phosphorylation (Figure 2A).
The potential contribution of Bad in fragment N-mediated cell
protection was assessed in MEFs derived from wild-type and Bad
knock-out mice. Figure 2B displays the possible outcome of
experiments using these cells expressing or not fragment N and
stimulated with increasing concentrations of cisplatin. As Bad
mediates part of the apoptotic response to cisplatin [53], reduced
cisplatin-induced death is expected in Bad knock-out (KO) MEFs
(orange lines). If Akt-induced Bad phosphorylation does not play
any role in the protection mediated by fragment N, the latter
should decrease the extent of apoptosis to similar extent in wild-
type and Bad KO MEFs (Figure 2B, left graph). In other words,
the maximal percent decrease in apoptosis induced by fragment N
should be similar in both MEF types as shown in the inset above
the left graph in Figure 2B. In contrast, if Bad phosphorylation is
the sole mechanism by which fragment N protects cells, the
sensitivity of Bad KO MEFs to cisplatin should be unaffected by
the presence of fragment N (Figure 2B, right graph). In this case,
for Bad KO cells, the difference between the apoptosis curves in
the presence or in the absence of fragment N should be minimal
(orange lines in the inset above the right graph in Figure 2B). The
middle graphs in Figure 2B display a situation where Bad
phosphorylation is partially contributing to fragment N-mediated
cell protection. The actual experiment (Figure 2C) generated a
pattern that corresponded to the scenario presented on the left of
Figure 2B, suggesting that Bad plays no or only minimal role in
fragment N-induced cell protection.
We reasoned that if Bad is not important for the capacity of
fragment N to inhibit apoptosis, fragment N should be able to
block cell death when the extrinsic pathway is activated, after Fas
ligand stimulation for example, because this mode of death is not
regulated by Bad. A potential caveat with this approach is that
there is a possibility of a connection of Fas-induced death signaling
to the intrinsic pathway via the cleavage of Bid [54]. This
connection with the intrinsic pathway of apoptosis can however be
blocked by over-expression of Bcl-2 [55]. Figure 2D shows that the
stimulation of the mitochondrial intrinsic pathway activated by
staurosporine in HeLa cells was fully prevented by Bcl-2 over-
expression (compare the 9th and 11th bars). HeLa cells are type 2
cells as inhibition of the intrinsic pathway reduces apoptosis
induced by Fas ligand (Figure 2D, compare the 5th and 7th bars);
see also [56]. Importantly, the remaining apoptotic response can
be fully blocked by fragment N (compare the 7th and 8th bars).
This indicates therefore that fragment N can protect cells against a
cell death stimulus in which pro-apoptotic Bcl-2 family members
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such as Bad play no role. Altogether, the experiments shown in
Figure 2 support the notion that Bad is not a critical target of
fragment N for its ability to protect cells.
Fragment N does not Regulate Survivin
There is evidence that Akt can induce survivin expression
[38,57,58]. As survivin may display anti-apoptotic activity in some
conditions [36–38,59,60], it could be one of the main targets of
fragment N that mediates its survival effects. We therefore assessed
whether fragment N can regulate survivin by determining if it
modulated its expression in vitro and in vivo and whether it affected
survivin capacity to regulate cell division.
The effect of fragment N on survivin transcription was assessed
by luciferase assay in which either the minimal or the entire
sequence of the mouse survivin promoter was used. Fragment N
expression in cells had no significant effect on either promoter
activities (Figure 3A). As a positive control for this experiment,
cells were transfected with an E2F1-expressing vector that is
known to mediate survivin transcription [61] and this resulted, as
expected, in an increase in survivin promoter activity (Figure 3A).
To further confirm these results, real time PCR was performed to
measure survivin mRNA in cells expressing or not fragment N.
Figure 3B shows that fragment N did not induce an increase in the
mRNA coding for survivin. Furthermore, survivin protein levels
were not affected by fragment N (Figure 3C).
We have recently demonstrated that UV-B exposure of the
epidermis leads to Akt phosphorylation in a caspase-3 and
RasGAP cleavage-dependent manner [10]. Moreover, it has also
been shown that survivin expression and relocalization to the
cytoplasm, where it is supposed to induce its anti-apoptotic
response [62], is induced in mouse skin in response to UV-B light
[46]. Given that fragment N induces Akt in the epidermis of UV-
B-irradiated mice [10] and that cytoplasmic survivin expression is
augmented in this same tissue [46], we tested whether survivin
expression in the skin is affected in knock-in (KI) mice that cannot
generate fragment N because of a mutation in the first caspase-3
cleavage site of RasGAP. Control and KI mice were exposed to
UV-B light 24 hours prior to biopsy and survivin levels were
monitored in the skin by immunofluorescence. The percentage of
keratinocytes expressing cytoplasmic survivin was increased by
UV-B in a dose-dependent manner. This increase was similar in
wild-type and KI mice (Figure 3D). This indicates that even
though the epidermis of mice unable to generate fragment N is
more sensitive to stress-induced apoptosis [10], it is still able to
induce cytoplasmic survivin expression to levels that are observed
in wild-type mice (Figure 3D). These results suggest that
cytoplasmic survivin is not involved in fragment N-mediated
protection, at least in mouse skin. Of note, the percentage of
keratinocytes expressing nuclear survivin was not affected by UV-
B light (Figure 3D).
Survivin is a protein with an important role in mitosis, with a
peak of expression at G2/M phase and is therefore highly
regulated in a cell cycle dependent manner [61,63]. Even though
fragment N does not appear to affect survivin levels, it may
regulate its well-described function during mitosis. In order to
study whether fragment N affects the cell cycle, cells expressing or
not fragment N were synchronized in G1 using a mimosine block
and then released from this block to resume cell cycling. Figure 4
shows that ectopic expression of fragment N did not alter the cell
cycle of HeLa cells. There is thus no evidence that fragment N
regulates survivin in vitro or in vivo.
In conclusion, the results presented in this work did not point to
a crucial role of a given Akt effector in fragment N-mediated cell
protection. Fragment N-mediated protection was not affected by
mTOR inhibition or in BAD KO cells. Furthermore, survivin
expression was neither modulated by fragment N nor was its
function impaired in cells unable to generate fragment N upon
stress. Possibly, fragment N relies on several Akt downstream
targets to mount an efficient cell survival response. Alternatively,
Akt effectors that we have not tested in the present work may fulfill
most of the anti-apoptotic response induced by fragment N.
Further studies need to be conducted to determine the exact
contribution of Akt targets that mediate the capacity of fragment
N to protect cells.
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